A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Fipravirimat (Primary) ; Dolutegravir; Emtricitabine/tenofovir alafenamide; Lamivudine/abacavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DOMINO
- Sponsors ViiV Healthcare
- 27 Feb 2024 This trial has been completed in Portugal(Global end date 29-May-2023) ,according to European Clinical Trials Database record.
- 26 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 11 Feb 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.